Adaptive Biotechnologies Corporation (ADPT)
Price:
16.21 USD
( + 0.16 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
NEWS
Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
defenseworld.net
2026-02-11 03:38:50Allianz Asset Management GmbH boosted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 305.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 321,774 shares of the company's stock after acquiring an additional 242,474 shares during the quarter. Allianz Asset
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-06 12:14:21Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock
defenseworld.net
2026-02-06 04:40:50Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.44, for a total value of $2,304,963.12. Following the completion of the sale, the chief executive officer directly owned 2,459,245 shares
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com
2026-02-05 20:30:21While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates
zacks.com
2026-02-05 18:35:29Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago.
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
2026-02-05 16:05:00SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
globenewswire.com
2026-01-27 16:05:00SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
globenewswire.com
2026-01-22 16:05:00SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies Corporation $ADPT Shares Bought by SG Americas Securities LLC
defenseworld.net
2026-01-19 05:24:58SG Americas Securities LLC increased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 82.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,113 shares of the company's stock after buying an additional 30,785 shares during
Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-12 22:35:58Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
globenewswire.com
2026-01-12 07:30:00SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024.
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $164,400.00 in Stock
defenseworld.net
2026-01-11 05:20:48Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) insider Harlan Robins sold 10,000 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.44, for a total transaction of $164,400.00. Following the completion of the transaction, the insider directly owned 1,222,312 shares of the
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock
defenseworld.net
2026-01-09 04:33:07Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $15.59, for a total transaction of $1,948,718.82. Following the completion of the transaction, the chief executive officer owned 2,584,243 shares of
Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech
geekwire.com
2026-01-06 11:51:43Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A investment round.
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $809,000 in Adaptive Biotechnologies Corporation $ADPT
defenseworld.net
2026-01-05 05:16:50VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 54,100 shares of the company's stock, valued at approximately $809,000. A number of other hedge funds have
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
2025-12-30 16:05:00SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
No data to display
Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
defenseworld.net
2026-02-11 03:38:50Allianz Asset Management GmbH boosted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 305.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 321,774 shares of the company's stock after acquiring an additional 242,474 shares during the quarter. Allianz Asset
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-06 12:14:21Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock
defenseworld.net
2026-02-06 04:40:50Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $18.44, for a total value of $2,304,963.12. Following the completion of the sale, the chief executive officer directly owned 2,459,245 shares
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com
2026-02-05 20:30:21While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates
zacks.com
2026-02-05 18:35:29Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago.
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
2026-02-05 16:05:00SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
globenewswire.com
2026-01-27 16:05:00SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
globenewswire.com
2026-01-22 16:05:00SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies Corporation $ADPT Shares Bought by SG Americas Securities LLC
defenseworld.net
2026-01-19 05:24:58SG Americas Securities LLC increased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 82.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,113 shares of the company's stock after buying an additional 30,785 shares during
Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
2026-01-12 22:35:58Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
globenewswire.com
2026-01-12 07:30:00SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024.
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $164,400.00 in Stock
defenseworld.net
2026-01-11 05:20:48Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) insider Harlan Robins sold 10,000 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.44, for a total transaction of $164,400.00. Following the completion of the transaction, the insider directly owned 1,222,312 shares of the
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock
defenseworld.net
2026-01-09 04:33:07Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $15.59, for a total transaction of $1,948,718.82. Following the completion of the transaction, the chief executive officer owned 2,584,243 shares of
Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech
geekwire.com
2026-01-06 11:51:43Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A investment round.
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $809,000 in Adaptive Biotechnologies Corporation $ADPT
defenseworld.net
2026-01-05 05:16:50VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 54,100 shares of the company's stock, valued at approximately $809,000. A number of other hedge funds have
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
2025-12-30 16:05:00SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.